Business Context and Reporting Period
Company: Drugs Made In America Acquisition Corp. (DMAA)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: The Company is a Cayman Islands-incorporated blank check company (SPAC) formed to effect a business combination with one or more businesses, primarily in the pharmaceutical industry. As of the reporting date, the Company had not commenced operations and generated no operating revenue. It is classified as an emerging growth company and a shell company.
Key Status Update: On April 29, 2026, the Company entered into a Definitive Merger Agreement with PAGC. The Company extended its combination period to April 29, 2027, subject to shareholder approval and funding of extension deposits.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net Income | $3,697,356 | $3,543,122 |
| Operating Expenses (G&A) | $280,235 | $462,844 |
| Interest Income (Trust Account) | $3,977,591 | $4,005,966 |
| Cash and Cash Equivalents (Outside Trust) | $20,280 | $822 |
| Cash and Investments in Trust Account | $146,834,251 | $239,906,656 |
| Total Assets | $146,903,435 | $239,918,847 |
| Total Liabilities | $9,136,624 | $7,276,172 |
| Working Capital Deficit | ($2,875,440) | ($363,981) |
| Shares Outstanding (Total) | 24,276,913 | N/A |
| Shares Subject to Redemption | 13,559,770 | 23,000,000 |
Material Changes vs. Prior Period
- Significant Share Redemptions: In connection with an extension vote on April 27, 2026, holders of 9,440,230 shares exercised redemption rights. Approximately $99.3 million was withdrawn from the Trust Account, reducing the Trust balance from ~$240 million to ~$147 million.
- Extension Funding: To extend the combination period, the Company received $600,000 in extension deposits from an investor (BV Advisory Partners, LLC) during the period, recorded as "Extension Advance Notes."
- Debt and Financing: The Company issued an "Interim Note" of $350,000 to an investor. The deferred underwriting fee payable was reduced by $708,000 due to the share redemptions, bringing the balance to $6,192,000.
- Operating Expenses: General and administrative costs decreased significantly year-over-year (from $462,844 to $280,235 for the six-month period), partly due to the cancellation of the administrative support agreement with the Sponsor in March 2026.
- Sponsor Default: The original Sponsor defaulted on a share subscription receivable. Consequently, 45,092 ordinary shares are subject to cancellation and surrender, though they remain outstanding pending formal cancellation.
Outlook, Risks, and Management Commentary
- Merger Agreement: The Company is pursuing a business combination with PAGC. A third amendment to the Merger Agreement was approved by the Boards on July 14, 2026 (subsequent event).
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern within one year due to the mandatory liquidation date and working capital deficit. The Company relies on completing the business combination to resolve this.
- Extension Mechanics: The combination period has been extended to April 29, 2027. Extensions require deposits of the lesser of $300,000 or $0.04 per non-redeemed share. As of July 27, 2026, an additional $300,000 was deposited for a one-month extension.
- Internal Controls: The Company disclosed that its disclosure controls and procedures were not effective as of June 30, 2026, citing material weaknesses including inadequate segregation of duties, insufficient written policies, and a lack of formal review processes for related party transactions.
- Risk Factors: Risks include the inability to complete the business combination, geopolitical instability affecting markets, and the potential for the Sponsor to be unable to fulfill financial obligations.
Investor Verification Checklist
- Merger Status: Verify the current status of the Definitive Merger Agreement with PAGC and the likelihood of closing before the April 29, 2027 deadline.
- Liquidity Runway: Confirm the sufficiency of the $20,280 cash balance outside the Trust Account to fund operations until the merger closes or liquidation occurs.
- Extension Funding: Monitor the ability of the Investor (BV Advisory Partners, LLC) to continue funding monthly extension deposits ($300,000/month) if the merger is delayed.
- Internal Controls: Assess the remediation plan for the material weaknesses in internal controls over financial reporting disclosed in Item 4.
- Sponsor Transition: Verify the resolution of the Sponsor's default on the share subscription receivable and the status of the 45,092 shares subject to cancellation.